<DOC>
	<DOCNO>NCT02801487</DOCNO>
	<brief_summary>The purpose study determine maximal tolerate dose ( MTD ) re-irradiation use carbon ion radiotherapy ( CIRT ) along concurrent chemotherapy treatment locally recurrent nasopharyngeal cancer ( NPC ) evaluate efficacy treatment MTD . Participants treat CIRT escalate dose regimen along concurrent chemotherapy ( 40 mg/m^2 , weekly ) evaluate maximal tolerate dose ( MTD ) term acute subacute toxicity observe within 4 month completion concurrent chemoradiotherapy . Once MTD locally recurrent NPC determine , MTD use recommend dose patient fulfil inclusion criterion Phase II part trial .</brief_summary>
	<brief_title>Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy Locally Recurrent Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>The purpose study determine maximal tolerate dose ( MTD ) re-irradiation use carbon ion radiotherapy ( CIRT ) along concurrent chemotherapy treatment locally recurrent nasopharyngeal cancer ( NPC ) evaluate efficacy treatment MTD set concurrent chemoradiotherapy . Participants treat CIRT escalate dose start 52.5GyE ( 2.5GyE/daily fraction ) potentially 62.5GyE ( 2.5GyE/daily fraction ) along concurrent chemotherapy ( 40 mg/m^2 , weekly ) evaluate maximal tolerate dose ( MTD ) term acute subacute toxicity observe within 4 month completion concurrent chemoradiotherapy . Time-to-event continual reassessment method ( TITE-CRM ) use phase I dose escalate part trial approximately 25 patient accrue . Once MTD set concurrent chemoradiotherapy locally recurrent NPC determine , MTD use recommend dose patient fulfil inclusion criterion Phase II part trial . The Phase II part trial single phase single arm study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Pathologically confirm NPC Completed definitive course intensitymodulated photon radiation therapy ( IMXT ) total dose ≥ 66 Gy Recurrence diagnose 12 month initial course IMXT Age ≥ 18 &lt; 70 year age Karnofsky Performance Score ≥70 Willing accept adequate contraception woman childbearing potential Ability understand character individual consequence clinical trial Willing sign write informed consent ; Informed consent must sign enrollment trial Local recurrence NPC diagnose within 12 month completion previous course radiation therapy Presence distant metastasis Technology use IMXT ( include brachytherapy follow IMXT ) treatment initial diagnosis NPC Pregnant lactate woman Patients yet recover acute toxicity prior therapy A diagnosis malignancy CIS cervix , BCC SCC skin within past 5 year Refusal patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Carbon Ion Therapy</keyword>
	<keyword>Concurrent Chemoradiotherapy</keyword>
</DOC>